Effects of lipid association on lomustine (CCNU) administered intracerebrally to syngeneic 36B-10 rat brain tumors

Cancer Letters

Volumn 244, Issue 2, 2006, Pages 211-219

  Yimam, Mesfin A ^a   Bui, Tot ^a   Ho, Rodney J Y ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

36B 10 Glioma; Lipid associated CCNU; Local drug delivery; Stereotactic

Indexed keywords

LIPID; LOMUSTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; EVALUATION; FEMALE; GLIOMA CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SPECIES COMPARISON; TREATMENT INDICATION; TUMOR MODEL; TUMOR REGRESSION; TUMOR VOLUME;

ALKYLATING AGENTS; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; ETHYLNITROSOUREA; FEMALE; INJECTIONS, INTRAVENTRICULAR; LIPOSOMES; LOMUSTINE; MALE; PHOSPHOLIPIDS; RATS; RATS, INBRED F344;

ANIMALIA;

EID: 33749364625     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.12.024     Document Type: Article

References (24)

1. Davis F.G., Freels S., Grutsch J., Barlas S., and Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (seer) data. J. Neurosurg. 88 1 (1998) 1-10
2. Perry J.R., DeAngelis L.M., Schold Jr. S.C., Burger P.C., Brem H., Brown M.T., et al. Challenges in the design and conduct of phase iii brain tumor therapy trials. Neurology 49 4 (1997) 912-917
3. Nagahiro S., Yamamoto Y.L., Diksic M., Mitsuka S., Sugimoto S., and Feindel W. Neurotoxicity after intracarotid 1,3-bis(2-chloroethyl)-1-nitrosourea administration in the rat: Hemodynamic changes studied by double-tracer autoradiography. Neurosurgery 29 1 (1991) 19-25 (discussion 26)
4. Carter S.K., Schabel Jr. F.M., Broder L.E., and Johnston T.P. 1,3-Bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review. Adv. Cancer Res. 16 (1972) 273-332
5. Bethune C.R., Geyer R.J., Spence A.M., and Ho R.J. Lipid association improves the therapeutic index of lomustine [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea] to suppress 36b-10 tumor growth in rats. Cancer Res. 61 9 (2001) 3669-3674
6. Barth R.F. Rat brain tumor models in experimental neuro-oncology: the 9l, c6, t9, f98, rg2 (d74), rt-2 and cns-1 gliomas. J. Neurooncol. 36 1 (1998) 91-102
7. Bethune C., Blum A., Geyer J.R., Silber J.R., and Ho R.J. Lipid association increases the potency against primary medulloblastoma cells and systemic exposure of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (ccnu) in rats. Pharm. Res. 16 6 (1999) 896-903
8. Spence A.M., and Coates P.W. Scanning electron microscopy of cloned astrocytic lines derived from ethylnitrosourea-induced rat gliomas. Virchows Arch. B Cell Pathol. 28 1 (1978) 77-85
9. Kobayashi N., Allen N., Clendenon N.R., and Ko L.W. An improved rat brain-tumor model. J. Neurosurg. 53 6 (1980) 808-815
10. Spence A.M., and Coates P.W. Scanning and transmission electron microscopy of cloned rat astrocytoma cells treated with dibutyryl cyclic amp in vitro. J. Cancer Res. Clin. Oncol. 100 1 (1981) 51-58
11. Parker S.L., Tong T., Bolden S., and Wingo P.A. Cancer statistics, 1996, CA. Cancer J. Clin. 46 1 (1996) 5-27
12. Hochberg F.H., and Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 30 9 (1980) 907-911
13. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 9311 (2002) 1011-1018
14. Westphal M., Hilt D.C., Bortey E., Delavault P., Olivares R., Warnke P.C., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (bcnu) wafers (gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 5 2 (2003) 79-88
15. Brem H., and Gabikian P. Biodegradable polymer implants to treat brain tumors. J. Control. Release 74 1-3 (2001) 63-67
16. Weinkam R.J., Finn A., Levin V.A., and Kane J.P. Lipophilic drugs and lipoproteins: partitioning effects on chloroethylnitrosourea reaction rates in serum. J. Pharmacol. Exp. Ther. 214 2 (1980) 318-323
17. Mayer L.D., Bally M.B., Cullis P.R., Wilson S.L., and Emerman J.T. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the sc115 murine mammary tumor. Cancer Lett. 53 2-3 (1990) 183-190
18. Huang S.K., Lee K.D., Hong K., Friend D.S., and Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52 19 (1992) 5135-5143
19. Witham T.F., Villa L., Yang T., Pollack I.F., Okada H., Robbins P.D., et al. Expression of a soluble transforming growth factor-beta (tgfbeta) receptor reduces tumorigenicity by regulating natural killer (nk) cell activity against 9l gliosarcoma in vivo. J. Neurooncol. 64 1-2 (2003) 63-69
20. Aas A.T., Brun A., Blennow C., Stromblad S., and Salford L.G. The rg2 rat glioma model. J. Neurooncol. 23 3 (1995) 175-183
21. Saini M., Bellinzona M., Meyer F., Cali G., and Samii M. Morphometrical characterization of two glioma models in the brain of immunocompetent and immunodeficient rats. J. Neurooncol. 42 1 (1999) 59-67
22. Parsa A.T., Chakrabarti I., Hurley P.T., Chi J.H., Hall J.S., Kaiser M.G., et al. Limitations of the c6/wistar rat intracerebral glioma model: Implications for evaluating immunotherapy. Neurosurgery 47 4 (2000) 993-999 (discussion 999-1000)
23. Morantz R.A., Wood G.W., Foster M., Clark M., and Gollahon K. Macrophages in experimental and human brain tumors. Part 1: studies of the macrophage content of experimental rat brain tumors of varying immunogenicity. J. Neurosurg. 50 3 (1979) 298-304
24. Spence A.M., and Priestley G. A survey of ethylnitrosourea-induced rat gliomas for the presence of tumour rejection antigens expressed in vivo. Neuropathol. Appl. Neurobiol. 7 1 (1981) 63-75